Nanjing Univ. of Chinese Medicine NLRP3 compound B6

Nanjing Univ. of Chinese Medicine NLRP3 compound B6: sourced facts only. name: "Mechanistically, B6 did not inhibit LPS-induced priming of the NLRP3 inflammasome, but significantly blocked NLRP3 inflammasome assembly by directly binding to NLRP3 and disrupting the NEK7-NLRP3 interaction." [PMID:40451138]; target: "Mechanistically, B6 did not inhibit LPS-induced priming of the NLRP3 inflammasome, but significantly blocked NLRP3 inflammasome assembly by directly binding to NLRP3 and disrupting the NEK7-NLRP3 interaction." [PMID:40451138]; developer: "Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China; State Key Laboratory of Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Nanjing University of Chinese Medicine, Nanjing, 210023, China." [PMID:40451138]; stage: "In vivo studies demonstrated that B6 was more effective than MCC950 in multiple NLRP3-driven diseases model, including systemic inflammation, peritonitis, and colitis." [PMID:40451138]